FGFR3 and cancer: In these cancers, pemigatinib has shown an ability to substantially inhibit tumor progression and induce partial responses, thereby extending survival in a subset of patients who have limited treatment options.13 The implications of these findings for GB, especially for the uncommon cases involving FGFR3 fusion genes, are intriguing.